Evidence map›Paper›PMID 37115924›Full record

ArticleScience advances2023

Pathophysiology of reinfection by exogenous HSV-1 is driven by heparanase dysfunction.

Rahul K Suryawanshi, Chandrashekhar D Patil, Alex Agelidis, Raghuram Koganti, Tejabhiram Yadavalli, Joshua M Ames, Hemant Borase, Deepak Shukla

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Microorganisms · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Rahul K SuryawanshiDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0001-8374-669X
Chandrashekhar D PatilDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0002-5641-4523
Alex AgelidisDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.
Raghuram KogantiDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0002-6551-2475
Tejabhiram YadavalliDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0001-8584-2685
Joshua M AmesDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0002-9282-5637
Hemant BoraseDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0003-2097-1018
Deepak ShuklaDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0002-3039-6953
University of Illinois Chicago · US

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MCANANY, JAMES JASON · 1985 to 2025
$14.8M
A new molecular therapy against ocular herpesR01EY024710 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DEEPAK SHUKLA · 2015 to 2026
$5.2M
HPSE in Ocular Herpes InfectionR01EY029426 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DEEPAK SHUKLA · 2018 to 2026
$3.7M
HSV-1 Encoded MicroRNAs in the Pathogenesis and Treatment of Ocular HerpesR01EY033622 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI NAQVI, AFSAR RAZA, SHUKLA, DEEPAK · 2022 to 2025
$1.6M
A small molecule inhibitor of HSV genital infectionsR01AI139768 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHUKLA, DEEPAK · 2018 to 2021
$1.6M
NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY024710NEI NIH HHS R01 EY029426NEI NIH HHS R01 EY033622NIAID NIH HHS R01 AI139768
6 · The paper itself

Abstract

Limited knowledge exists on exogenous DNA virus reinfections. Herpes simplex virus-1 (HSV-1), a prototype DNA virus, causes multiple human diseases including vision-threatening eye infections. While reinfection with an exogenous HSV-1 strain is considered plausible, little is known about the underlying mechanisms governing its pathophysiology in a host. Heparanase (HPSE), a host endoglycosidase, when up-regulated by HSV-1 infection dictates local inflammatory response by destabilizing tissue architecture. Here, we demonstrate that HSV-1 reinfection in mice causes notable pathophysiology in wild-type controls compared to the animals lacking HPSE. The endoglycosidase promotes infected cell survival and supports a pro-disease environment. In contrast, lack of HPSE strengthens intrinsic immunity by promoting cytokine expression, inducing necroptosis of infected cells, and decreasing leukocyte infiltration into the cornea. Collectively, we report that immunity from a recent prior infection fails to abolish disease manifestation during HSV-1 reinfection unless HPSE is rendered inactive.

Indexed as

Herpes SimplexHerpesvirus 1, HumanAnimalsGlucuronidaseHeparanaseHumansMiceReinfectionGlucuronidaseHeparanase

Identifiers

PMID37115924
PMCPMC10146881
OpenAlexW4367308577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.